Surmodics
Market Cap
US$525.9m
Last Updated
2020/09/24 05:37 UTC
Data Sources
Company Financials +
Executive Summary
Surmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and internationally. More Details
Rewards
Risk Analysis
Snowflake Analysis
Flawless balance sheet with reasonable growth potential.
Share Price & News
How has Surmodics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SRDX's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
1.5%
SRDX
-3.3%
US Medical Equipment
-3.3%
US Market
1 Year Return
-14.4%
SRDX
13.7%
US Medical Equipment
10.9%
US Market
Return vs Industry: SRDX underperformed the US Medical Equipment industry which returned 14.7% over the past year.
Return vs Market: SRDX underperformed the US Market which returned 13.1% over the past year.
Shareholder returns
| SRDX | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.5% | -3.3% | -3.3% |
| 30 Day | -16.8% | -2.5% | -5.7% |
| 90 Day | -4.0% | 12.2% | 8.2% |
| 1 Year | -14.4%-14.4% | 14.7%13.7% | 13.4%10.9% |
| 3 Year | 23.9%23.9% | 69.0%64.7% | 34.9%25.9% |
| 5 Year | 76.4%76.4% | 140.9%122.6% | 84.6%63.8% |
Price Volatility Vs. Market
How volatile is Surmodics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
What Can We Make Of Surmodics' (NASDAQ:SRDX) CEO Compensation?4 months ago | Simply Wall St
Investors Who Bought Surmodics (NASDAQ:SRDX) Shares Three Years Ago Are Now Up 65%5 months ago | Simply Wall St
Why You Should Care About Surmodics, Inc.’s (NASDAQ:SRDX) Low Return On CapitalValuation
Is Surmodics undervalued compared to its fair value and its price relative to the market?
68.42x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: SRDX ($38.54) is trading above our estimate of fair value ($23.63)
Significantly Below Fair Value: SRDX is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: SRDX is poor value based on its PE Ratio (68.4x) compared to the US Medical Equipment industry average (49.6x).
PE vs Market: SRDX is poor value based on its PE Ratio (68.4x) compared to the US market (17.8x).
Price to Earnings Growth Ratio
PEG Ratio: SRDX is poor value based on its PEG Ratio (1.6x)
Price to Book Ratio
PB vs Industry: SRDX is overvalued based on its PB Ratio (4x) compared to the US Medical Equipment industry average (3.9x).
Next Steps
Future Growth
How is Surmodics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
42.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SRDX's forecast earnings growth (42.7% per year) is above the savings rate (2.2%).
Earnings vs Market: SRDX's earnings (42.7% per year) are forecast to grow faster than the US market (23% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: SRDX's revenue (9.9% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: SRDX's revenue (9.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SRDX's Return on Equity is forecast to be low in 3 years time (6.7%).
Next Steps
Past Performance
How has Surmodics performed over the past 5 years?
-28.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SRDX has a large one-off loss of $1.7M impacting its June 30 2020 financial results.
Growing Profit Margin: SRDX's current net profit margins (7.4%) are higher than last year (2.5%).
Past Earnings Growth Analysis
Earnings Trend: SRDX's earnings have declined by 28.5% per year over the past 5 years.
Accelerating Growth: SRDX's earnings growth over the past year (225.4%) exceeds its 5-year average (-28.5% per year).
Earnings vs Industry: SRDX earnings growth over the past year (225.4%) exceeded the Medical Equipment industry 1.8%.
Return on Equity
High ROE: SRDX's Return on Equity (5.8%) is considered low.
Next Steps
Financial Health
How is Surmodics's financial position?
Financial Position Analysis
Short Term Liabilities: SRDX's short term assets ($87.8M) exceed its short term liabilities ($15.6M).
Long Term Liabilities: SRDX's short term assets ($87.8M) exceed its long term liabilities ($20.3M).
Debt to Equity History and Analysis
Debt Level: SRDX is debt free.
Reducing Debt: SRDX has not had any debt for past 5 years.
Debt Coverage: SRDX has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: SRDX has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Next Steps
Dividend
What is Surmodics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SRDX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SRDX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SRDX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SRDX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SRDX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.3yrs
Average management tenure
CEO
Gary Maharaj (57 yo)
9.75yrs
Tenure
US$2,343,629
Compensation
Mr. Gary R. Maharaj has been the Chief Executive Officer and President at Surmodics, Inc. since December 27, 2010. Mr. Maharaj served as the Chief Executive Officer and President at Arizant Inc. from 2006 ...
CEO Compensation Analysis
Compensation vs Market: Gary's total compensation ($USD2.34M) is about average for companies of similar size in the US market ($USD2.02M).
Compensation vs Earnings: Gary's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 9.75yrs | US$2.34m | 0.99% $ 5.2m | |
| Senior VP of Finance & Information Technology and CFO | 2.33yrs | US$816.56k | 0.38% $ 2.0m | |
| Senior VP of Product Development & Chief Marketing Officer | 1.83yrs | US$1.30m | 0.10% $ 547.0k | |
| Chief Operating Officer of Medical Devices | 4.83yrs | US$847.13k | 0.22% $ 1.2m | |
| Corporate Controller & Principal Accounting Officer | 2.33yrs | no data | 0.017% $ 90.1k | |
| Senior VP of Legal | 0.33yr | no data | 0.020% $ 106.4k | |
| Senior VP & GM of Human Resources - In Vitro Diagnostics | 0.42yr | US$696.13k | 0.38% $ 2.0m | |
| Senior Vice President of Commercial & Business Development - Medical Devices | 15.92yrs | US$903.23k | 0.30% $ 1.6m | |
| Vice President of Research & Development - Medical Devices | 4.67yrs | US$864.91k | 0.19% $ 973.6k |
2.3yrs
Average Tenure
54.5yo
Average Age
Experienced Management: SRDX's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 9.75yrs | US$2.34m | 0.99% $ 5.2m | |
| Independent Director | 4.75yrs | US$145.50k | 0% $ 0 | |
| Independent Director | 6.58yrs | US$156.00k | 0% $ 0 | |
| Independent Director | 9.67yrs | US$151.00k | 0.017% $ 89.5k | |
| Independent Chairman of the Board | 5.67yrs | US$219.00k | 0.11% $ 594.6k | |
| Independent Director | 18.67yrs | US$148.00k | 0.017% $ 89.6k | |
| Independent Director | 3.42yrs | US$144.00k | 0.014% $ 73.2k |
6.6yrs
Average Tenure
64yo
Average Age
Experienced Board: SRDX's board of directors are considered experienced (6.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Surmodics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Surmodics, Inc.
- Ticker: SRDX
- Exchange: NasdaqGS
- Founded: 1979
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$525.885m
- Shares outstanding: 13.65m
- Website: https://www.surmodics.com
Number of Employees
Location
- Surmodics, Inc.
- 9924 West 74th Street
- Eden Prairie
- Minnesota
- 55344
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| SRDX | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Mar 1998 |
| SU6 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Mar 1998 |
Biography
Surmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and internationally. The company operates thro ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/09/24 05:37 |
| End of Day Share Price | 2020/09/23 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/09/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.